HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tio, R. A. Articles by Zijlstra, F. Search for Related Content PubMed PubMed Citation Articles by Tio, R. A. Articles by Zijlstra, F.

PET for Evaluation of Differential Myocardial Perfusion Dynamics After VEGF Gene Therapy and Laser Therapy in End-Stage Coronary Artery Disease

¹ Department of Cardiology, University Hospital Groningen, Groningen, The Netherlands
² Trial Coordination Center, University Hospital Groningen, Groningen, The Netherlands
³ Department of Nuclear Medicine, University Hospital Groningen, Groningen, The Netherlands
⁴ PET Center, University Hospital Groningen, Groningen, The Netherlands
⁵ Department of Medical Oncology, University Hospital Groningen, Groningen, The Netherlands

View larger version (37K): [in a new window]   FIGURE 1. (A) Static image of long-axis views of NH3 PET scan at rest (left) and during dipyridamole stress (right). Top 2 panels, at baseline; bottom 2 panels, at follow-up. (B) Polar map reconstruction of scans shown in A: VEGF-treated patient showing marked improvement in perfusion and reduction of anginal complaints. Top 2 panels, at baseline; bottom 2 panels, at follow-up; left-hand panels, rest; right-hand panels, dipyridamole stress. (C) Polar map of DMR patient showing no improvement in perfusion images or in anginal complaints. Top 2 panels, at baseline; bottom 2 panels, at follow-up; left-hand panels, rest; right-hand panels, dipyridamole stress.

View larger version (15K): [in a new window]   FIGURE 2. (A) CCS angina pectoris classification at baseline and after 3 mo of follow-up in 3 groups (control, standard therapy; DMR, laser treatment; VEGF, VGEF gene therapy). Changes were significantly different between the 3 groups (P < 0.001). (B) Change in CCS class in 3 individual groups. Change in VEGF gene therapy group was significantly different from that of other 2 groups (P < 0.05).